Safety of anti-IL-23 risankizumab treatment in a patient with severe psoriasis and Charcot-Marie-Tooth disease

被引：0
|
作者：
Carugno, Andrea [1 ,2 ]
Brigenti, Noemi [3 ]
Gisondi, Paolo [3 ]
Al Ghadban, Zeina [4 ]
Parietti, Michele [1 ]
Vezzoli, Pamela [1 ]
Sena, Paolo [1 ]
Pisciotta, Chiara [5 ]
机构：
[1] ASST Papa Giovanni XXIII, Dermatol Unit, Piazza OMS 1, Bergamo, Italy
[2] Univ Milano Bicocca, PhD Program Mol & Translat Med DIMET, Milan, Italy
[3] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy
[4] Univ Milano Bicocca, Sch Med & Surg SMS, Milan, Italy
[5] Fdn IRCCS Ist Neurol Carlo Besta, Dept Clin Neurosci, Milan, Italy
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷 / 04期
关键词：
Charcot-Marie-Tooth; demyelinating neurological disorders; interleukin (IL)-23; psoriasis; risankizumab;
D O I：
10.1111/ajd.14154
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：e376 / e378
页数：3
相关论文
共 38 条
  • [31] A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis
    Shi, Jianzhen
    Xu, Jianru
    Chen, Yanmei
    DERMATOLOGIC THERAPY, 2020, 33 (04)
  • [32] Efficacy and safety of risankizumab in psoriasis patients who failedanti-IL-17, anti-12/23 and/or antiIL-23: Preliminary data of a real-life 16-week retrospective study
    Megna, Matteo
    Fabbrocini, Gabriella
    Ruggiero, Angelo
    Cinelli, Eleonora
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [33] Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study
    Gargiulo, Luigi
    Ibba, Luciano
    Narcisi, Alessandra
    Giordano, Silvia
    Maronese, Carlo A.
    Martora, Fabrizio
    Repetto, Federica
    Paolino, Giovanni
    Balato, Anna
    Burlando, Martina
    Dapavo, Paolo
    Dini, Valentina
    Guarneri, Claudio
    Marzano, Angelo V.
    Megna, Matteo
    Mercuri, Santo R.
    Costanzo, Antonio
    Valenti, Mario
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2024, 14 (04):
  • [34] Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
    Cui, Lian
    Chen, Rongfen
    Subedi, Smriti
    Yu, Qian
    Gong, Yu
    Chen, Zeyu
    Shi, Yuling
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 : 46 - 58
  • [35] A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
    Bilal, Jawad
    Berlinberg, Adam
    Bhattacharjee, Sandipan
    Trost, Jaren
    Bin Riaz, Irbaz
    Kurtzman, Drew J. B.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (06) : 569 - 578
  • [36] Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
    Krueger, James G.
    Ferris, Laura K.
    Menter, Alan
    Wagner, Frank
    White, Alexander
    Visvanathan, Sudha
    Lalovic, Bojan
    Aslanyan, Stella
    Wang, Elaine E. L.
    Hall, David
    Solinger, Alan
    Padula, Steven
    Scholl, Paul
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (01) : 116 - U231
  • [37] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Randazzo, Bruce
    Wasfi, Yasmine
    Shen, Yaung-Kaung
    Li, Shu
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 405 - 417
  • [38] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    Li, Shu
    Shen, Y. -K.
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 418 - 431
1234